<DOC>
	<DOC>NCT00557427</DOC>
	<brief_summary>The study is a pilot study where adolescents 12 - 18 years of age with mild to moderate depression will be randomized to receive either hypericum 250mg twice daily or fluoxetine 10mg daily increased to 20mg daily after 1 week and the option to increase to 40mg daily after 4 weeks. Patients will be treated for a total of 8 weeks. Efficacy will be measured using the CDRS-R, BDI-II and the CGI scales. Safety parameters include blood tests, urinalysis and ECG.</brief_summary>
	<brief_title>Hypericum vs Fluoxetine for Mild to Moderate Adolescent Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<criteria>Signed informed consent Adolescents aged 12 to 18 years Patients meeting the criteria for mild to moderate depression according to the DSMIV scale Physical and laboratory examination at baseline compatible with study criteria ECG at baseline compatible with study criteria Score of at least 40 on the Children's Depression Rating Scale Revised (CDRSR) at baseline Patients with psychosis, bipolar disease, schizophrenia or significant developmental disorder Patients with epilepsy Patients with a history of alcohol or substance abuse in the past year Initiation of psychotherapy or behavioral therapy in the 2 months prior to screening or during the study. Patients who have previously failed to respond to SSRI's or SRNI's Patients who have been treated with antidepressants within 2 weeks of screening (4 weeks if fluoxetine) Patients with a contraindication to taking either Remotiv or fluoxetine or taking medication contraindicated when taking Remotiv or fluoxetine</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>mild to moderate depression according to the DSM-IV scale</keyword>
</DOC>